520 related articles for article (PubMed ID: 30979816)
1. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
3. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
4. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
[TBL] [Abstract][Full Text] [Related]
6. Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer.
Yuan W; Deng D; Jiang H; Tu C; Shang X; He H; Niu R; Dong J
Cancer Immunol Immunother; 2019 Feb; 68(2):257-268. PubMed ID: 30406373
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
8. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
[TBL] [Abstract][Full Text] [Related]
9. Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
Theelen WSME; Kuilman T; Schulze K; Zou W; Krijgsman O; Peters DDGC; Cornelissen S; Monkhorst K; Sarma P; Sumiyoshi T; Amler LC; Willems SM; Blaauwgeers JLG; van Noesel CJM; Peeper DS; van den Heuvel MM; Kowanetz M
PLoS One; 2019; 14(5):e0216864. PubMed ID: 31125352
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells.
Sp N; Kang DY; Lee JM; Jang KJ
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576006
[TBL] [Abstract][Full Text] [Related]
11. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
12. Follicular helper T cells promote the effector functions of CD8
Shi W; Dong L; Sun Q; Ding H; Meng J; Dai G
Exp Cell Res; 2018 Nov; 372(1):35-42. PubMed ID: 30205088
[TBL] [Abstract][Full Text] [Related]
13. Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression.
Liu X; Zhou Z; Cheng Q; Wang H; Cao H; Xu Q; Tuo Y; Jiang L; Zou Y; Ren H; Xiang M
Cell Death Dis; 2017 Sep; 8(9):e3033. PubMed ID: 28880262
[TBL] [Abstract][Full Text] [Related]
14. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
[TBL] [Abstract][Full Text] [Related]
15. Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling.
Chen Q; Zhuang S; Hong Y; Yang L; Guo P; Mo P; Peng K; Li W; Xiao N; Yu C
Oncogene; 2022 Mar; 41(10):1421-1433. PubMed ID: 35027670
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
17. A combination of stromal PD-L1 and tumoral nuclear β-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.
Takahashi H; Watanabe H; Hashimura M; Matsumoto T; Yokoi A; Nakagawa M; Ishibashi Y; Ito T; Ohhigata K; Saegusa M
J Pathol Clin Res; 2022 Sep; 8(5):458-469. PubMed ID: 35762092
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5.
Li Z; Zhou J; Zhang J; Li S; Wang H; Du J
Int J Cancer; 2019 Oct; 145(7):1946-1957. PubMed ID: 30873585
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
20. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]